In Silico Analysis to Identify IL-6 Inhibitor from Antiviral Compounds of Kabasurakudineer Extract against COVID-19

ABSTRACT

Background: Novel coronavirus (COVID-19) is an infectious disease which causes the outbreak as a pandemic and reiterated the call for countries to take immediate actions and proportion response to treat, detect and cut back transmission to save lots of people's lives. Several targeting specific functional proteins and ligands against coronavirus have been reported to prevent replication of virus RNA. Aim(s) The study was aimed to targetthe interleukin-6 protein, that may further block the binding of the virus to human cell receptor and signal transduction which activate the intracellular JAK-MAPK (Janus Kinase\Mitogenactivated protein kinase) and JAK- STAT3 (Janus Kinase/Signal Transducer and Activator of Transcription) signaling pathways. Method(s) In this study, we selected 36 reported compounds and 2 standard anti-HIV drugs such as Abacavir and Hydroxychloroquine for the inhibition of IL-6 protein. It has been reportable with their antiviral efficacies against alternative virus-infected diseases. Molecular docking analyses were performed to identify the best affinity compound against IL-6. Result(s) Among 38 reported compounds, gallic acid and luteolin are the best binding affinity against Interleukin-6 protein. Conclusion(s) Therefore, the results suggest that gallic acid and luteolin has a potential inhibitory function against IL-6 protein, which inhibits the interaction and signal transduction of the virus with the host cell and it provide a potential lead molecule for the development of a new drug against COVID-19disease. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.